Clinical Efficacy of Dasatinib, Nilotinib and Imatinib in Newly Diagnosed Patients with Chronic-Phase Chronic Myeloid Leukemia: A Three-year Retrospective Analysis / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 356-363, 2015.
Article
en Zh
| WPRIM
| ID: wpr-259585
Biblioteca responsable:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate efficacy and safety of second-generation tyrosine kinase inhibitors (TKI) dasatinib, nilotinib and imatinib in treatment of newly diagnosed patients with chronic-phase chronic myeloid leukemia (CML).</p><p><b>METHODS</b>The clinical data and follow-up results of 163 patients with chronic-phase chronic myeloid lenkemia(CP-CML) who were treated in our hospital during the nearly 3 years were analysed retrospectively, among 163 patients 47 received dasatinib, 43 received nilotinib and 73 received imatinib. The efficacy, disease progression and safety were evaluated.</p><p><b>RESULTS</b>After treatment for 3 months, the rate of complete hematologic response(CHR) in three treatment groups were 77%, 79% and 67%, respectivily, CHR at 12 months in three treatment groups were 92%, 91% and 90%, respectively. By 3 months, the rates of complete cytogenetic response(CCyR) with dasatinib and nilotinib were higher than that with imatinib (55%, 53% vs 33%)(P<0.05 for both comparisons), CCyR at 12 months in three treatment groups were 86%, 88% vs 69% (P<0.05 for both comparisons). The rates of major molecular response(MMR) for dasatinib (11%) and nilotinib (9%) by 3 months were significantly higher than that for imatinib (1%) (P<0.05 for both comparisons), MMR at 12 months in three treatment groups were 49%, 50% and 28%, respectively (P<0.05 for both comparison). Progression to the accelerated or blast phase of CML occurred in 2 (4%) patients received dasatinib, 2 (5%) received nilotinib and 6 (8%) received imatinib. The safety profiles of these 3 second-generation TKI treatments were similar.</p><p><b>CONCLUSION</b>Both dasatinib and nilotinib induced strikingly higher and faster rates of complete cytogenetic response and major molecular response, with a statistically significant difference from imatinib.</p>
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Pirimidinas
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Crisis Blástica
/
Estudios Retrospectivos
/
Resultado del Tratamiento
/
Progresión de la Enfermedad
/
Inhibidores de Proteínas Quinasas
/
Mesilato de Imatinib
/
Dasatinib
Tipo de estudio:
Observational_studies
Límite:
Humans
Idioma:
Zh
Revista:
Journal of Experimental Hematology
Año:
2015
Tipo del documento:
Article